Drugs Made In America Acquisition reported no operating revenue for the periods covered, recording interest income of $8.76 million from its IPO trust that contributed to $5.94 million of net income in one reporting period while posting a $0.28 million net loss for the period May 23, 2024 through December 31, 2024 driven by general and administrative costs. The company has not commenced operations and therefore has no revenue-generating activities or operating results to report. Net income per share was not provided.
Financial Highlights
- Revenue: $0.00 — no operating revenues to date; only non-operating interest income recorded from trust account.
- Net Income: $5.94 million — primarily comprised of $8.76 million interest income from the trust offset by $2.82 million general and administrative expenses (which include $1.996 million non-cash share issuance).
- Net Loss: $0.280 million — for the period May 23, 2024 through December 31, 2024, consisting of general and administrative costs.
- Other: Interest income from trust accounted for the only recorded income; no gross profit, operating income, or EPS figures were provided in the filing excerpts.
Business Highlights
- Initial Public Offering & Trust Funding: Completed IPO and overallotment, placing $231.15 million in a trust to finance an initial business combination.
- Operational Status: Has not commenced operations; expected to generate revenue only after completing an initial business combination.
- Search & Transaction Activity: Actively pursuing target(s); incurred due diligence, offering, and transaction costs and issued interim financing commitments.
- Sponsor Transition & Financing: Original sponsor acknowledged inability to fund; a new investor provided an interim convertible note and a $500,000 financing agreement is underway to support transaction activities.
- Target Focus & Strategy: Exploring an enterprise technology opportunity in AI/ML, quantum analytics, and cybersecurity consistent with the company’s stated strategy.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.